

Part VI: Summary of the risk management plan

Summary of risk management plan for Hydromorphone

This is a summary of the risk management plan (RMP) for Hyfilax. The RMP details important risks of Hyfilax and how more information will be obtained about hydromorphone's risks and uncertainties (missing information).

Hyfilax's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Hyfilax should be used.

I. The medicine and what it is used for

This medicine contains the active substance hydromorphone hydrochloride, which is a potent analgesic (potent "painkiller") of the opioid group. Hyfilax is used for the treatment of severe pain. Hydromorphone solution for injection or infusion is available in strengths of 2 mg/ml, 10 mg/ml, 20 mg/ml and 50 mg/ml.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Hyfilax, together with measures to minimise such risks and the proposed studies for learning more about Hyfilax's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

If important information that may affect the safe use of Hyfilax is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Hyfilax are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a causal relationship with the use of Hyfilax. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none"> • Respiratory depression
Important potential risks	<ul style="list-style-type: none"> • none
Missing information	<ul style="list-style-type: none"> • none

II.B Summary of important risks

The safety information in the proposed product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Hyfilax.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Hyfilax.